Sotera Health Company (SHC) Investor Day 2024 summary
Event summary combining transcript, slides, and related documents.
Investor Day 2024 summary
8 Jul, 2026Strategic priorities and market positioning
Focus on four key priorities: customer excellence, targeting growth markets, operational excellence, and disciplined capital allocation for incremental value creation.
Operates in large, highly regulated markets with high barriers to entry and strong customer relationships, with 70%+ revenue from multi-year contracts.
Emphasizes cross-business synergies, especially between Sterigenics and Nelson Labs, to drive integrated solutions and higher customer satisfaction.
Strategic segmentation targets higher-growth, higher-profitability areas such as diabetes, bioprocessing, wearables, and select pharma segments.
M&A remains a focus, with tuck-in and adjacent market acquisitions considered, but not included in current forecasts.
Financial performance and guidance
Achieved 8% CAGR in revenue and Adjusted EBITDA since 2020, with free cash flow growing at 10% CAGR.
Targets 5%-7% annual revenue growth and 5%-8% Adjusted EBITDA growth from 2025-2027, with $500M+ cumulative free cash flow and 35% EBITDA conversion by 2027.
Margin expansion of at least 50 basis points expected, driven by operational leverage and cost management.
CapEx to peak in 2025, then decline as major projects complete, supporting improved free cash flow.
Pricing tailwind adjusted to 3%-4% (from prior 3.5%-5%), mainly due to normalization in Nordion pricing.
Business unit highlights
Nelson Labs: Expanding pharma testing, investing in rapid testing and cleanrooms, and leveraging cross-business integration for growth and margin improvement.
Sterigenics: Leading global sterilization provider, investing $170M in EO facility upgrades to meet new regulations, and targeting mid- to high-single-digit growth.
Nordion: Global leader in Cobalt-60, securing long-term supply through investments in new reactor capabilities and exploring radiopharma opportunities.
All units benefit from durable customer relationships, high regulatory barriers, and integrated service offerings.
Latest events from Sotera Health Company
- Strong 2025 outlook with stable operations, regulatory-driven consolidation, and disciplined growth.SHC
Jefferies Global Healthcare Conference 20259 Jul 2026 - Growth accelerates, modernization advances, and M&A focus sharpens amid effective risk management.SHC
Wolfe Research Healthcare Conference 20259 Jul 2026 - 2025 guidance targets 4%-6% revenue growth, margin expansion, and lower CapEx amid FX risks.SHC
Q4 20248 Jul 2026 - Q1 2025 revenue and EBITDA grew, but net loss resulted from a $31M EO litigation settlement.SHC
Q1 20258 Jul 2026 - CEO transition, regulatory investments, and global expansion drive growth and resilience.SHC
Goldman Sachs 47th Annual Global Healthcare Conference 20268 Jun 2026 - Leadership transition, steady growth, and robust supply chain investments drive positive outlook.SHC
Jefferies Global Healthcare Conference 20263 Jun 2026 - All proposals passed with strong support amid continued financial growth and strategic focus.SHC
AGM 202621 May 2026 - Strong demand, margin recovery, and new leadership drive positive outlook for the year.SHC
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Q1 2026 delivered 10% revenue growth, margin expansion, and reaffirmed a strong 2026 outlook.SHC
Q1 20265 May 2026